{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T06:02:03Z","timestamp":1792735323481,"version":"4.5.0"},"reference-count":34,"publisher":"BMJ","funder":[{"name":"Fili\u00e8re Muco-CFTR and Soci\u00e9t\u00e9 Fran\u00e7aise de la Mucoviscidose","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"name":"Vaincre la Mucoviscidose","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Thorax"],"accepted":{"date-parts":[[2026,8,6]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>This study sought to describe the prevalence of lung hyperinflation in adults (\u226518 years) with cystic fibrosis (awCF) and the effects of elexacaftor-tezacaftor-ivacaftor (ETI) on hyperinflation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Consecutive awCF who initiated ETI at Cochin Hospital (Paris, France) and had performed body plethysmography within 12 months prior to ETI initiation were included. Abnormal lung volumes (including total lung capacity (TLC) and residual volume (RV)) were defined as &gt; upper limit of normal (ULN) using the Global Lung Initiative reference values. Lung hyperinflation was defined as RV\/TLC&gt;ULN. Variables associated with hyperinflation prior to ETI initiation were identified using multivariate logistic regression analysis. Evolution of hyperinflation was examined by comparing data prior to and after 12 months on ETI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Findings<\/jats:title>\n                    <jats:p>\n                      Body plethysmography was available prior to ETI initiation in 297 awCF, of which 286 had also body plethysmography at 12 months after ETI initiation. Prior to ETI initiation, TLC, RV and RV\/TLC ratio values greater than ULN were found in 14%, 69% and 76% of awCF, respectively. RV\/TLC ratio inversely correlated with percent predicted forced expiratory volume in 1\u2009s (ppFEV\n                      <jats:sub>1<\/jats:sub>\n                      ; r=\u22120.86). Increasing age and the number of days on intravenous antibiotics in the previous year were independently associated with RV\/TLC&gt;ULN. RV\/TLC decreased after 12 months of ETI (median (IQR) absolute decrease; \u22125.4 (\u221210.3 to \u22120.3) %, p&lt;0.0001; n=286) but remained above ULN in 65% of awCF, including in some with normal ppFEV\n                      <jats:sub>1<\/jats:sub>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interpretation<\/jats:title>\n                    <jats:p>\n                      Lung hyperinflation usually persists in awCF treated with ETI despite improvement in ppFEV\n                      <jats:sub>1<\/jats:sub>\n                      and lung volumes.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/thorax-2026-225174","type":"journal-article","created":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T17:20:29Z","timestamp":1787073629000},"page":"thorax-2026-225174","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Persistence of static lung hyperinflation in adults with cystic fibrosis treated with elexacaftor-tezacaftor-ivacaftor"],"prefix":"10.1136","author":[{"given":"Th\u00e9o","family":"Dhote","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine, National Reference Cystic Fibrosis Center, Cochin Hospital, Assistance Publique-H\u00f4pitaux de Paris, Paris, France"},{"name":"Institut Cochin, Universit\u00e9 Paris Cit\u00e9, Inserm, CNRS, Paris, France"},{"name":"ERN-Lung Cystic Fibrosis Network, Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9mence","family":"Martin","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, National Reference Cystic Fibrosis Center, Cochin Hospital, Assistance Publique-H\u00f4pitaux de Paris, Paris, France"},{"name":"Institut Cochin, Universit\u00e9 Paris Cit\u00e9, Inserm, CNRS, Paris, France"},{"name":"ERN-Lung Cystic Fibrosis Network, Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Fajac","sequence":"additional","affiliation":[{"name":"Institut Cochin, Universit\u00e9 Paris Cit\u00e9, Inserm, CNRS, Paris, France"},{"name":"ERN-Lung Cystic Fibrosis Network, Frankfurt, Germany"},{"name":"Department of Physiology, Cochin Hospital, Assistance Publique H\u00f4pitaux de Paris, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9rique","family":"Aubourg","sequence":"additional","affiliation":[{"name":"Department of Physiology, Cochin Hospital, Assistance Publique H\u00f4pitaux de Paris, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reem","family":"Kanaan","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, National Reference Cystic Fibrosis Center, Cochin Hospital, Assistance Publique-H\u00f4pitaux de Paris, Paris, France"},{"name":"ERN-Lung Cystic Fibrosis Network, Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Carlier","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, National Reference Cystic Fibrosis Center, Cochin Hospital, Assistance Publique-H\u00f4pitaux de Paris, Paris, France"},{"name":"ERN-Lung Cystic Fibrosis Network, Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Honor\u00e9","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, National Reference Cystic Fibrosis Center, Cochin Hospital, Assistance Publique-H\u00f4pitaux de Paris, Paris, France"},{"name":"ERN-Lung Cystic Fibrosis Network, Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Fesenbeckh","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, National Reference Cystic Fibrosis Center, Cochin Hospital, Assistance Publique-H\u00f4pitaux de Paris, Paris, France"},{"name":"ERN-Lung Cystic Fibrosis Network, Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Da Silva","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, National Reference Cystic Fibrosis Center, Cochin Hospital, Assistance Publique-H\u00f4pitaux de Paris, Paris, France"},{"name":"ERN-Lung Cystic Fibrosis Network, Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Perez","sequence":"additional","affiliation":[{"name":"Lung Function Department, CHU de Lille, Lille, France"},{"name":"CIIL - Center for Infection and Immunity of Lille, Lille, France"},{"name":"CNRS UMR 9017, Lille, France"},{"name":"INSERM U1019, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0903-9828","authenticated-orcid":false,"given":"Pierre-R\u00e9gis","family":"Burgel","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, National Reference Cystic Fibrosis Center, Cochin Hospital, Assistance Publique-H\u00f4pitaux de Paris, Paris, France"},{"name":"Institut Cochin, Universit\u00e9 Paris Cit\u00e9, Inserm, CNRS, Paris, France"},{"name":"ERN-Lung Cystic Fibrosis Network, Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,8,18]]},"reference":[{"key":"2026081810202070000_thorax-2026-225174v1.1","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41572-024-00538-6","article-title":"Cystic fibrosis","volume":"10","author":"Mall","year":"2024","journal-title":"Nat Rev Dis Primers"},{"key":"2026081810202070000_thorax-2026-225174v1.2","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.diii.2025.09.003","article-title":"Identification of structural predictors of lung function improvement in adults with cystic fibrosis treated with elexacaftor-tezacaftor-ivacaftor using deep-learning","volume":"107","author":"Chassagnon","year":"2026","journal-title":"Diagn Interv Imaging"},{"key":"2026081810202070000_thorax-2026-225174v1.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2022.07.004"},{"key":"2026081810202070000_thorax-2026-225174v1.4","doi-asserted-by":"publisher","DOI":"10.1126\/science.ade2216"},{"key":"2026081810202070000_thorax-2026-225174v1.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1908639"},{"key":"2026081810202070000_thorax-2026-225174v1.6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32597-8"},{"key":"2026081810202070000_thorax-2026-225174v1.7","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1056\/NEJMoa2100665","article-title":"Triple Therapy for Cystic Fibrosis Phe508del-Gating and -Residual Function Genotypes. Reply","volume":"385","author":"Barry","year":"2021","journal-title":"N Engl J Med"},{"key":"2026081810202070000_thorax-2026-225174v1.8","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/S2213-2600(24)00208-X","article-title":"The expanded French compassionate programme for elexacaftor-tezacaftor-ivacaftor use in people with cystic fibrosis without a F508del CFTR variant: a real-world study","volume":"12","author":"Burgel","year":"2024","journal-title":"Lancet Respir Med"},{"key":"2026081810202070000_thorax-2026-225174v1.9","doi-asserted-by":"crossref","first-page":"01783","DOI":"10.1183\/13993003.01783-2025","article-title":"Advances in cystic fibrosis: CFTR modulator triple combinations","volume":"67","author":"Burgel","year":"2026","journal-title":"Eur Respir J"},{"key":"2026081810202070000_thorax-2026-225174v1.10","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202108-1986OC"},{"key":"2026081810202070000_thorax-2026-225174v1.11","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1513\/AnnalsATS.202312-1065OC","article-title":"Multisystemic Effects of Elexacaftor-Tezacaftor-Ivacaftor in Adults with Cystic Fibrosis and Advanced Lung Disease","volume":"21","author":"Burgel","year":"2024","journal-title":"Ann Am Thorac Soc"},{"key":"2026081810202070000_thorax-2026-225174v1.12","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S2213-2600(19)30049-9","article-title":"Exploring the relevance and extent of small airways dysfunction in asthma (ATLANTIS): baseline data from a prospective cohort study","volume":"7","author":"Postma","year":"2019","journal-title":"Lancet Respir Med"},{"key":"2026081810202070000_thorax-2026-225174v1.13","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jaip.2025.08.013","article-title":"Detecting Small Airways Dysfunction in Asthma: Rationale, Findings, and Future of ATLANTIS","volume":"14","author":"Siddiqui","year":"2026","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2026081810202070000_thorax-2026-225174v1.14","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.2147\/COPD.S458324","article-title":"Lung Hyperinflation as Treatable Trait in Chronic Obstructive Pulmonary Disease: A Narrative Review","volume":"19","author":"Koopman","year":"2024","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2026081810202070000_thorax-2026-225174v1.15","doi-asserted-by":"crossref","DOI":"10.1186\/1465-9921-7-138","article-title":"Progression of pulmonary hyperinflation and trapped gas associated with genetic and environmental factors in children with cystic fibrosis","volume":"7","author":"Kraemer","year":"2006","journal-title":"Respir Res"},{"key":"2026081810202070000_thorax-2026-225174v1.16","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200407-948OC"},{"key":"2026081810202070000_thorax-2026-225174v1.17","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1111\/crj.12763","article-title":"Static hyperinflation is associated with ventilatory limitation and exercise tolerance in adult cystic fibrosis","volume":"12","author":"Stevens","year":"2018","journal-title":"Clin Respir J"},{"key":"2026081810202070000_thorax-2026-225174v1.18","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.jcf.2021.03.016","article-title":"Peripheral lung effect of elexacaftor\/tezacaftor\/ivacaftor in adult cystic fibrosis","volume":"21","author":"Stylemans","year":"2022","journal-title":"J Cyst Fibros"},{"key":"2026081810202070000_thorax-2026-225174v1.19","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.chest.2024.03.033","article-title":"Relationship Between Lung Volumes and Heterogeneity in the Response to Elexacaftor\/Tezacaftor\/Ivacaftor in Patients With Cystic Fibrosis and Advanced Lung Disease","volume":"166","author":"Gramegna","year":"2024","journal-title":"Chest"},{"key":"2026081810202070000_thorax-2026-225174v1.20","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/S2213-2600(25)00190-0","article-title":"Sweat chloride and lung function responses to elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis with two versus one responsive CFTR variants: an analysis of two real-world observational studies","volume":"13","author":"Burgel","year":"2025","journal-title":"Lancet Respir Med"},{"key":"2026081810202070000_thorax-2026-225174v1.21","doi-asserted-by":"publisher","DOI":"10.1136\/thorax.57.8.742"},{"key":"2026081810202070000_thorax-2026-225174v1.22","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.05.00035005"},{"key":"2026081810202070000_thorax-2026-225174v1.23","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201908-1590ST"},{"key":"2026081810202070000_thorax-2026-225174v1.24","doi-asserted-by":"crossref","first-page":"00289","DOI":"10.1183\/13993003.00289-2020","article-title":"Official ERS technical standard: Global Lung Function Initiative reference values for static lung volumes in individuals of European ancestry","volume":"57","author":"Hall","year":"2021","journal-title":"Eur Respir J"},{"key":"2026081810202070000_thorax-2026-225174v1.25","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00080312"},{"key":"2026081810202070000_thorax-2026-225174v1.26","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200407-867OC"},{"key":"2026081810202070000_thorax-2026-225174v1.27","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/resp.12906","article-title":"Clinical value of pulmonary hyperinflation as a treatment outcome in cystic fibrosis","volume":"22","author":"Stevens","year":"2017","journal-title":"Respirology"},{"key":"2026081810202070000_thorax-2026-225174v1.28","doi-asserted-by":"crossref","first-page":"106713","DOI":"10.1016\/j.rmed.2021.106713","article-title":"The role of inspiratory capacity and tidal flow in diagnosing exercise ventilatory limitation in Cystic Fibrosis","volume":"192","author":"Reuveny","year":"2022","journal-title":"Respir Med"},{"key":"2026081810202070000_thorax-2026-225174v1.29","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01499-2021"},{"key":"2026081810202070000_thorax-2026-225174v1.30","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jcf.2025.10.005","article-title":"Limited impact of Elexacaftor\/Tezacaftor\/Ivacaftor on CPET outcomes in an Italian cohort of people with Cystic Fibrosis: reinforcing the essential role of exercise training","volume":"25","author":"Retucci","year":"2026","journal-title":"J Cyst Fibros"},{"key":"2026081810202070000_thorax-2026-225174v1.31","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201507-1281OC"},{"key":"2026081810202070000_thorax-2026-225174v1.32","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S2213-2600(22)00434-9","article-title":"Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials","volume":"11","author":"Mayer-Hamblett","year":"2023","journal-title":"Lancet Respir Med"},{"key":"2026081810202070000_thorax-2026-225174v1.33","doi-asserted-by":"crossref","first-page":"3752","DOI":"10.1002\/ppul.25649","article-title":"Impulse oscillometry indices to detect an abnormal lung clearance index in childhood cystic fibrosis","volume":"56","author":"Bokov","year":"2021","journal-title":"Pediatr Pulmonol"},{"key":"2026081810202070000_thorax-2026-225174v1.34","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.26635"}],"container-title":["Thorax"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/thorax-2026-225174","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T17:20:31Z","timestamp":1787073631000},"score":1,"resource":{"primary":{"URL":"https:\/\/thorax.bmj.com\/lookup\/doi\/10.1136\/thorax-2026-225174"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,18]]},"references-count":34,"alternative-id":["10.1136\/thorax-2026-225174"],"URL":"https:\/\/doi.org\/10.1136\/thorax-2026-225174","relation":{},"ISSN":["0040-6376","1468-3296"],"issn-type":[{"value":"0040-6376","type":"print"},{"value":"1468-3296","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,18]]}}}